BioCentury

Current Editions

October 25, 2021
Two years of gene therapy dealmaking

AAVs still center stage, but next-gen approaches starting to attract more partners

Data Byte

Product Development

What’s next for CRISPR & gene therapy, plus a China Summit Preview

Emerging Company Spotlight: Elpiscience and Rectify

Oct. 25 Quick Takes: FDA approves Bausch + Lomb’s Xipere 

Plus AstraZeneca, AnaptysBio, Novartis, Sanofi and more

Guest Commentary

Biopharma companies are still undervaluing external innovation

The case for being bolder and taking risks on early clinical deals

Finance

More crossovers join Cedilla’s series B, bringing total to $82.6M

Third Rock-backed oncology company adds four new investors in series B extension

Management Tracks

Immunomedics vet Itri takes CMO post at 

Plus Mersana, Athira, Aprecia and more

BioCentury ISSN 1097-7201